This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.
How will RFK Jr’s American dream for vaccines play out? The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. Give your business an edge with our leading industry insights.
How will RFK Jr’s American dream for vaccines play out? With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m.
How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
How will RFK Jr’s American dream for vaccines play out? The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. Give your business an edge with our leading industry insights.
It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. The below figure presents the distribution of subcutaneous biologics based on initial approval year and type of biologic.
million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Primary Packaging material designers. Secondary packagers. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. The global pre-filled syringes market was valued at $1139.6
This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. Sound familiar? Have a great day, everyone.
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. reaching £915 billion by 2027. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% Device Engineering. Human Factors. Injectables. Sterile Manufacturing.
4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™
The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.
How will RFK Jr’s American dream for vaccines play out? The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!
This law includes a broad package of provisions concerning healthcare, taxes, and climate change. Cost sharing for adult vaccines covered by Medicare Part D will be eliminated In 2020, more than 4 million Medicare beneficiaries received a vaccine covered under Part D, including 3.6 million who received the shingles vaccine.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content